The short answer: GLP-1 drugs work mainly by making you less hungry. They are a lab-made copy of a hormone your gut already releases every time you eat.
Your own version of that hormone lasts about two minutes. Your gut sends it out after a meal, it delivers its signal, and enzymes in your blood take it apart almost immediately, because it is built to be a brief message rather than something that lingers. The drug is that same hormone, rebuilt so it survives in your blood for about a week instead. That one change, two minutes to a week, sits behind most of what confuses people about these drugs: the weekly schedule, the nausea, why the dose starts low, why your friend’s prescription is not the same as yours, what happens if you stop, and why you lose muscle and bone density along with fat.
How do GLP-1s work in the body?
What is GLP-1?
GLP-1 is short for glucagon-like peptide-1. Your small intestine releases it every time you eat. Cells in your gut lining called L-cells push it into your bloodstream, and within about fifteen minutes there is two to four times more of it circulating than there was before the meal.
It carries one message: food is here.
That message goes to two places. Your pancreas reads it and adjusts your blood sugar, and your brain reads it and starts building the feeling of being full. None of this asks anything of you: your body runs it several times a day whether you think about it or not, and you never notice it happening. The drugs are copies of that same molecule, aimed at the same targets, and the only thing they change is how long the message lasts.
Why do GLP-1s make you less hungry?
The weight loss comes from eating less. These drugs act on the parts of your brain that handle hunger and reward. Appetite goes down, and so does the pull toward eating when you are not hungry.
A lot of coverage suggests these drugs speed up your metabolism or help you burn fat faster. They do not. They work at the other end, managing how much food you actually eat. You do not have to decide to eat less for this to happen, because the drug is doing that work.
The part people describe most often is not hunger at all. It is the constant background chatter about food, the planning and negotiating and thinking-about-lunch-during-breakfast that runs under everything else. People call it food noise, and when it goes quiet, that silence is usually the first thing they notice, often before the scale moves.
Why do GLP-1s make you feel nauseous?
The effect that helps you feel full is the same one that can make you feel nauseous. GLP-1 drugs slow how quickly your stomach empties. Food sits there longer, which adds to fullness, and which can also mean nausea, bloating, and getting full faster than you expect. It is usually worst in the first weeks and clusters around each dose increase.
The stomach effect probably matters less to your weight than the appetite effect does, and it tends to fade as your body adjusts while the appetite effect holds. Many people lose weight without ever feeling sick. If it does get bad enough to interfere with your life, that is a conversation with your prescriber rather than something to wait out alone, and there are practical ways to manage it in the meantime.
Why does the dose start low?
You do not start on the dose that does the work. Every one of these drugs climbs a ladder, and the reason is the slowed stomach emptying that causes nausea. Going up slowly gives your gut time to adjust, and moving faster mainly buys you more nausea.
Wegovy is the clearest example: it steps through 0.25, 0.5, 1.0, 1.7, and 2.4 mg, holding each for about four weeks, so reaching the full dose takes at least sixteen weeks. Only that last step is the dose proven to work, and everything below it exists to get you there. That is why the first months can feel like the drug is barely doing anything: it mostly isn’t yet, and the ladder is working as designed rather than failing.
Why is it a weekly shot?
Your own GLP-1 disappears almost immediately. An enzyme called DPP-4 breaks it down within about one to two minutes, and only about 10 to 15 percent of what your gut releases reaches your bloodstream intact.
That is a problem if you want to use it as a medicine, so the molecule was altered to resist that enzyme and given the ability to stick to albumin, a protein in your blood that keeps it in circulation for far longer. Those modifications slow down its breakdown and allow once-weekly dosing.
The weekly schedule applies to the injections. There is one pill version of semaglutide, sold as Rybelsus, and it is taken daily because very little of it survives the trip through your gut.
What is the difference between Ozempic, Wegovy, Mounjaro and Zepbound?
Ozempic and Wegovy both contain semaglutide, which acts on the GLP-1 signal and nothing else. Ozempic’s original approval is for type 2 diabetes and Wegovy’s is for weight management, though both have since added cardiovascular indications. Which one you are prescribed usually comes down to your diagnosis and your insurance rather than to which one is stronger.
| Brand | Molecule | Acts on | Original approval |
|---|---|---|---|
| Ozempic | semaglutide | GLP-1 | type 2 diabetes |
| Wegovy | semaglutide | GLP-1 | weight management |
| Mounjaro | tirzepatide | GLP-1 + GIP | type 2 diabetes |
| Zepbound | tirzepatide | GLP-1 + GIP | weight management |
| Rybelsus | semaglutide (oral) | GLP-1 | type 2 diabetes |
Mounjaro and Zepbound contain tirzepatide, which works on that signal and on a second gut hormone called GIP at the same time. That makes it a genuinely different medication rather than a stronger version of semaglutide, which is worth knowing if you are comparing what you were prescribed against what a friend takes. How much the second signal contributes on its own is still an open question, and we come back to it below.
What happens if you stop taking a GLP-1?
The drug works while it is in your body. When it leaves, the signal it was holding open closes again, appetite returns, and for most people much of the weight comes back. We go through what the withdrawal trials actually found separately. Trials have seen up to about two-thirds of the lost weight return within roughly a year of stopping.
Two honest qualifications. Regain is usually not total: in the tirzepatide and semaglutide withdrawal trials, people who stopped still ended up below where they started. And this is not evidence the drugs do not work. It is the same effect running in reverse, which is what you would expect from a treatment that works by being present.
Staying on it keeps the weight off, which is why these are increasingly described as treatments for a long-term condition rather than a course you finish. Whether that is right for you involves cost, side effects, and your own health picture, and it is a decision for you and a clinician rather than something this page can answer.
How much weight do people actually lose?
People on these drugs eat roughly 16 to 39 percent fewer calories than people on placebo. That range comes from a 2024 review by Christensen and colleagues, which pulled together ten studies measuring how much people on GLP-1s actually ate.
That range is wide for a reason. The studies used different comparisons and different ways of measuring, and the review added them up loosely rather than pooling them statistically, so the direction is solid but the exact figure is not. For one carefully measured example, in a 12-week study of 30 people taking semaglutide (the molecule in Ozempic and Wegovy) at 1 mg weekly, participants ate about 24 percent less across a day than they did on placebo.
How much, and how fast. In a two-year trial of semaglutide 2.4 mg, the Wegovy dose, weight loss reached about 15 percent by the end of the first year and then held roughly flat through the second, so the curve plateaus rather than continuing down or creeping back. That durability is what happens while you keep taking it.
The averages hide a wide spread, and this is the part worth knowing before you start. In that same trial at two years, about 77 percent of people had lost at least 5 percent of their body weight, about 52 percent reached 15 percent, and about 36 percent reached 20 percent. So “about 15 percent” is a middle, not a promise. A meaningful number of people lose considerably less.
What those studies did not look at. Most measured eating at a single test meal in a lab, not across a normal week at home. Only a few looked at what people ate rather than how much. We know the amount of food eaten goes down, but we don’t know much about what happens to the quality of the food.
What does this mean for you?
You will probably eat less without deciding to, and that happens whether or not you have a plan for what to eat. It makes the food you do eat matter more than it did before, because if you are eating meaningfully less for months, the same nutrients your body needs have to fit into a smaller amount of food, which is its own question about what to eat.
The drug lowers how much you eat, and the rest follows from that. Most of what comes off is fat. In the trial that measured this most carefully, the split was about three parts fat to one part lean tissue, and it was the same split in the people taking a placebo, so it reflects losing weight rather than anything the drug is doing. What the drug carries is no instruction to spare muscle and bone specifically. That is why you lose muscle, and why bone density falls, alongside the fat during fast weight loss. It is not a flaw in the drug and it is not a sign you are doing something wrong. It is a gap in what the drug was built to do, and it happens to be the part you can influence.
What can you do about it?
If you are still deciding
Treat it as ongoing, not as a course you finish. The single most useful thing to understand before starting is that the effect lasts while the drug does. Deciding to start is closer to deciding to manage something long term than deciding to do a program for six months.
Ask what the plan is, not just what the dose is. Worth asking a prescriber: how long does it take to reach the full dose, what happens if the side effects are bad on the way up, what is the plan if I want to stop, and what would make you tell me to call rather than wait.
Expect a range, not a number. Most people lose meaningful weight and a minority lose very little, and there is no reliable way to know in advance which you will be.
If you are already taking one
Eat enough protein. During weight loss, roughly 80 to 120 grams a day is the target most clinicians work from, and we grade the evidence behind that number separately. Three things worth knowing about that number: the research behind it is often funded by companies that sell protein, it is measured in people dieting rather than people specifically on GLP-1s, and every study behind it was run in people with normal kidney function, so if you have kidney disease the right target is a question for the clinician managing it.
Lift something heavy, regularly. Resistance training is the most reliable way to hold onto muscle while you lose weight. Those trials were run in dieters and older adults rather than in people on GLP-1s, but muscle responds to loading the same way regardless of why the weight is coming off.
Track something other than the scale. How many stairs you can climb, whether you can carry the groceries in one trip, how far you can walk or run. The scale cannot tell you what kind of weight you lost, which is what our body-recomposition calculator is for.
What do we still not know?
How much the second hormone adds. Tirzepatide acts on GIP as well as GLP-1, and the drug works well, but how much of that is GIP doing something on its own is not settled.
Whether food can do a version of this. Fiber and unsaturated fats do raise your own GLP-1. That work is mostly in animals and small human studies, and the effect is nowhere near what the drugs produce. Eat fiber for the many other reasons to eat fiber. Do not expect it to stand in for a medication.
Sources and review
How GLP-1 works in the body
- Bodnaruc AM, Prud’homme D, Blanchet R, Giroux I. Nutritional modulation of endogenous glucagon-like peptide-1 secretion: a review. Nutr Metab (Lond). 2016;13(1). doi:10.1186/s12986-016-0153-3
- Baggio LL, Drucker DJ. Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight. J Clin Invest. 2014;124(10):4223-4226. doi:10.1172/jci78371
How much people eat on these drugs
- Christensen S, Robinson K, Thomas S, Williams DR. Dietary intake by patients taking GLP-1 and dual GIP/GLP-1 receptor agonists: A narrative review and discussion of research needs. Obes Pillars. 2024;11:100121. doi:10.1016/j.obpill.2024.100121
- Blundell J, Finlayson G, Axelsen M, et al. Effects of once‐weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017;19(9):1242-1251. doi:10.1111/dom.12932
How much weight comes off, and over how long
- Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083-2091. doi:10.1038/s41591-022-02026-4
What happens after stopping
- Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. doi:10.1111/dom.14725
- Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity. JAMA. 2021;325(14):1414. doi:10.1001/jama.2021.3224
- Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity. JAMA. 2024;331(1):38. doi:10.1001/jama.2023.24945
Side effects
- Klein KR, Clemmensen KKB, Fong E, Olsen S, Abrahamsen T, Lingvay I. Occurrence of Gastrointestinal Adverse Events Upon GLP-1 Receptor Agonist Initiation With Concomitant Metformin Use: A Post Hoc Analysis of LEADER, STEP 2, SUSTAIN-6, and PIONEER 6. Diabetes Care. 2024;47(2):280-284. doi:10.2337/dc23-1791
Holding on to muscle while losing weight
- Eglseer D, Traxler M, Embacher S, et al. Nutrition and Exercise Interventions to Improve Body Composition for Persons with Overweight or Obesity Near Retirement Age: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. Adv Nutr. 2023;14(3):516-538. doi:10.1016/j.advnut.2023.04.001
- Sardeli AV, Komatsu TR, Mori MA, Gáspari AF, Chacon-Mikahil MPT. Resistance Training Prevents Muscle Loss Induced by Caloric Restriction in Obese Elderly Individuals: A Systematic Review and Meta-Analysis. Nutrients. 2018;10(4):423. doi:10.3390/nu10040423
Pharmacology, dose ladders, and the dual-agonist designation
- US FDA, Center for Drug Evaluation and Research. Summary Review (Cross-Discipline Team Leader Review), NDA 209637, Ozempic (semaglutide). Approved December 5, 2017. accessdata.fda.gov
- US FDA, Center for Drug Evaluation and Research. Deputy Division Director Summary Review for Regulatory Action, NDA 215256, Wegovy (semaglutide 2.4 mg injection). Approved June 4, 2021. accessdata.fda.gov
- US FDA, Center for Drug Evaluation and Research. Summary Review (Cross-Discipline Team Leader Review), NDA 215866, Mounjaro (tirzepatide). Approved May 13, 2022. accessdata.fda.gov
Not yet medically reviewed. This page is in editorial review. A named clinical reviewer and review date are required before it is indexed, per the style guide.